Angelalign released its 2026 half-year report, showing net profit attributable to the parent company fell 6.3% year-on-year to 118 million yuan in the first half. Operating revenue was 302 million yuan, down 0.3% year-on-year. Deducted non-recurring net profit attributable to the parent was 99.54 million yuan, down 10.7%. Net operating cash flow was 143 million yuan, up 89.5%. Second-quarter net profit attributable to the parent was 61.33 million yuan, down 12.1% year-on-year. The company continues to focus on the research, development, production and sales of minimally invasive endoscopic diagnostic and therapeutic devices. Domestic market sales revenue declined, while overseas market sales revenue achieved growth.
Hangzhou AGS MedTech Co. Ltd. ANet profit attributable to parent fell 6.3% year-on-year to 118 million yuan in H1, with operating revenue down 0.3%.
